U.S. officials have arrested Enochian BioSciences co-founder Serhat Gümrükcü. | U.S. officials have arrested Enochian BioSciences co-founder Serhat Gümrükcü. The researcher is charged with conspiring to use interstate commerce facilities in the commission of murder-for-hire which … | Continue reading
Kaleido Therapeutics has faced the music. The microbiome-focused biotech is packing up shop after a dismal eight months of setbacks punctuated by its failure to find a buyer. | Kaleido Therapeutics failed to find a buyer, so it's closing up shop. That means its remaining staff ar … | Continue reading
We finally know who Moderna has been courting behind the scenes to make the big jump into gene editing. | We finally know who Moderna has been courting behind the scenes to make the big jump into gene editing. The famed biotech has signed a research partnership with CRISPR gene e … | Continue reading
COVID-19 wasn’t even in the picture when mRNA was developed as a new medicine, but with the regulatory runway cleared, biotechs that have been working on the tech for years are ready for liftoff. | Continue reading
Pfizer’s oral COVID-19 antiviral has cut the risk of hospitalization or death by 85% in a late-phase trial, prompting the Big Pharma to stop the study and race to seek emergency use authorization from the FDA. | Continue reading
The brain stimulation system includes a small device implanted on the patient’s brain that continuously monitors neurological activity and instructs two leads in separate areas of the brain to emit pulses if abnormal activity is detected. | Continue reading
In vitro tests have found that the radiofrequency sensor technology was able to measure glucose levels with accuracy comparable to that of Abbott’s Freestyle Libre continuous glucose monitor. | Continue reading
A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing. Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical trials after the FDA cleared an investigational new drug application. | Continue reading
Humane Genomics is building a platform that can design cancer-killing viruses from scratch and test them more quickly than other methods. It is working on viruses that not only target cancer cells while sparing healthy ones but that can also carry drugs to boost the virus’s effec … | Continue reading
Rejuvenate Bio raised more than $10 million in its series A round to propel its gene therapy toward the market for the treatment of heart disease in dogs and toward the clinic for the treatment of aging-related conditions in humans, including heart failure, kidney failure, Type 2 … | Continue reading
Move over, gene editing: There’s a new kid on the block. Tessera Therapeutics is pioneering “gene writing,” a kind of genetic medicine it hopes will surmount the limitations of gene editing and gene therapy—and investors have bet more than $230 million on the approach. | Continue reading
The FDA has authorized the use of its first digital, machine-learning-powered device to help screen people for COVID-19. | Continue reading
The amyloid theory continues to grasp at life as Eli Lilly has unveiled new phase 2 data from donanemab that show it can help Alzheimer’s disease patients by clearing these plaques out of the brain. | Continue reading
The robots are coming: After working under the radar for four years, Bionaut Labs is raising the curtain on its tiny, remote-controlled devices, built to travel through the human body and deliver a dose of medicine where it’s needed the most. | Continue reading
2020 didn't match 2018's record-breaking performance in the new drug approvals department, but it came pretty darn close. | Continue reading
The new vaccine technology mRNA is making waves these days as COVID-19 shots based on it deliver efficacy that’s unrivaled by other platforms. BioNTech's Pfizer-partnered vaccine Comirnaty is one of those vaccines. Now, the German biotech’s CEO, Ugur Sahin, has led a study showin … | Continue reading
Pfizer and BioNTech have shared (PDF) phase 1/2 data suggesting their COVID-19 vaccine triggers stronger CD8 T-cell responses than Moderna’s rival candidate. Four-fifths of subjects who received BNT162b1 had vaccine-induced CD8 T-cell responses and researchers classed most of the … | Continue reading
About a year and a half after receiving approval from the FDA as a first-line treatment for mesothelioma, Novocure has secured a CE mark for its Tumor Treating Fields therapy in Europe. | Continue reading
The first data are in for Regeneron’s COVID-19 antibody cocktail—and they’re encouraging. The top dose of the treatment lowered virus levels and relieved symptoms more quickly than placebo in patients infected with COVID-19 but not sick enough to be hospitalized. | Continue reading
Since launching Grail into the world in 2016, Illumina has watched the cancer blood test developer grow into a multibillion-dollar startup enterprise by amassing multiple nine-digit funding rounds. | Continue reading
Fitbit’s latest smartwatch has now secured medical device clearances in the U.S. and Europe, unlocking the full use of its ECG app to help identify cases of the irregular heart rhythm known as atrial fibrillation. | Continue reading
The FDA authorized its first COVID-19 diagnostic test for use with pools of samples, in a move to let laboratories conserve resources by evaluating groups of people at once. | Continue reading
A single injection of the gene that makes the protein follistatin caused a significant buildup of muscle mass in mice while also preventing obesity, reported Washington University researchers. The gene therapy could someday help people who are overweight and suffering from joint … | Continue reading
A phase 1 trial of Moderna’s COVID-19 vaccine candidate has begun enrolling subjects at the highest dose. Moderna shared the update on the COVID-19 study alongside news that people in another trial had anti-Zika antibodies after receiving the biotech’s vaccine against that virus. | Continue reading
Roche received a green light from the FDA for emergency use of its high-volume coronavirus diagnostic, the first commercially developed test to do so. The agency said it approved the test within 24 hours of receiving the application. | Continue reading
Noninfectious viruses used to deliver gene therapy can still sometimes touch off dangerous immune responses. A team from Johns Hopkins Medicine has developed an alternative method for transporting large therapies into cells—including genes and even the gene-editing system CRISPR. … | Continue reading
Scientists at Arizona State University have set eyes on a new source of cancer-specific neoantigens, known as frameshift peptides, to help design vaccines that can treat or prevent tumor progression—and they have positive results from mouse studies. | Continue reading
Though Editas and Allergan are not the first companies to test a CRISPR-based medicine in humans—that distinction goes to CRISPR Therapeutics and Vertex—their treatment is the first that edits DNA within the body. | Continue reading
MYC is an oncogene that’s linked to many cancer types, including prostate cancer. But it’s also a notoriously undruggable target. Now, scientists led by Cold Spring Harbor Laboratory have found a way to indirectly control MYC, which they believe could offer a new strategy for tre … | Continue reading
Scientists from the University of Wisconsin-Madison and the University of Texas at Austin have turned to the jawless sea lamprey for inspiration in developing a new way to bypass the blood-brain barrier and ferry drugs directly to previously difficult-to-access diseased sites. | Continue reading